Peptilogics
Pittsburg, US · Founded 2013 · Delaware corporation · 9 known investors
Peptilogics is a clinical-stage surgical therapeutics company developing zaloganan (PLG0206), a novel anti-biofilm drug to treat and prevent medical device-related infections such as prosthetic joint infections. Its lead candidate is in a pivotal Phase 2/3 trial and holds FDA Orphan Disease, Fast Track, and QIDP designations.
BiotechHealthtechMedical Devices
Founders & leadership
Peptilogics was founded in 2013 by Jonathan Steckbeck.
JS
Jonathan SteckbeckFounder
Board
SD
Investors · 9
AAF Management Ltd.Washington
Alpha Wave GlobalMiami
AMR Action FundBoston
Mountain State CapitalMorgantown · $200K – $500K
Narya CapitalColumbus
Riverfront Ventures, LLCPittsburgh · $250K – $1M
Tachyon VenturesLos Angeles
Lead Edge CapitalreportedNew York · $50M – $400Mvia Stephan Dietrich · board
TT6reportedWalnut
Reported raises · per SEC filings
Form D private placements$40.9M disclosed across 4 rounds · 2016–2020
▶$35.8MraisedDec 2020 · 19 investors · BiotechnologyRule 506(b)
▶$35.8MraisedDec 2020 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan SteckbeckExecutive Officer, Director
- Dietrich StephanDirector
- Hannes HolsteDirector
- Jason CammDirector
- Catherine MottDirector
- Offering amount
- $35.8M
- Amount sold
- $35.8M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedAug 2017 · 1 investors · BiotechnologyRule 506(b)
▶$4MraisedAug 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan SteckbeckExecutive Officer, Director
- Stefan RoeverDirector
- Sanjay KakkarExecutive Officer, Director
- Catherine MottDirector
- Dietrich StephanDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$754KraisedMay 2017 · 7 investors · BiotechnologyRule 506(b)
▶$754KraisedMay 2017 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stefan RoeverDirector
- Catherine MottDirector
- Jonathan SteckbeckExecutive Officer, Director
- Dietrich StephanDirector
- Offering amount
- $1.5M
- Amount sold
- $754K
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$416.8KraisedJan 2016 · 2 investors · BiotechnologyRule 506(b)
▶$416.8KraisedJan 2016 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephan DietrichDirector
- Jonathan SteckbeckExecutive Officer, Director
- Offering amount
- $1.6M
- Amount sold
- $416.8K
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapAbiologics34 shared keywordsAbiologics uses generative AI and high-throughput chemical protein synthesis to design and produce Synteins, a new class of programmable, protease-resistant, immune-silent biologic therapeutics. The company targets a range of disease areas, including oncology, immunology, and metabolic diseases.
Epi Biologics24 shared keywordsEpibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
Macrogenics Inc19 shared keywordsMacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients. It advances a pipeline of product candidates using proprietary platforms for antibody-drug conjugates, bispecific checkpoint antibodies, and T-cell engagers.
Bioworld18 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Peptilogics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Peptilogics do?
- Peptilogics is a clinical-stage surgical therapeutics company developing zaloganan (PLG0206), a novel anti-biofilm drug to treat and prevent medical device-related infections such as prosthetic joint infections. Its lead candidate is in a pivotal Phase 2/3 trial and holds FDA Orphan Disease, Fast Track, and QIDP designations.
- Who founded Peptilogics?
- Peptilogics was founded by Jonathan Steckbeck in 2013.
- Who are Peptilogics's investors?
- Peptilogics's investors include AAF Management Ltd., Alpha Wave Global, AMR Action Fund, Mountain State Capital, Narya Capital, Riverfront Ventures, LLC, Tachyon Ventures, Lead Edge Capital and 1 more.
- How much funding has Peptilogics raised?
- Peptilogics has disclosed $40.9M raised across 4 rounds.
- Where is Peptilogics headquartered?
- Peptilogics is headquartered in Pittsburg, US.